The board of directors of CombiGene AB (publ) (”CombiGene”) has, on the basis of an authorisation from the Annual General Meeting, resolved on a directed issue of 1,322,751 new shares to Lipigon Pharmaceuticals AB (”Lipigon”) due to the license agreement that CombiGene has entered into with Lipigon, which has reinforced CombiGene’s position as Sweden’s leading gene therapy company.
The share issue is conducted in order to settle the upfront payment to Lipigon in accordance with the license agreement and results in a dilution of approximately 2 percent of the share capital of CombiGene after the new issue of shares.
The upfront payment amounts to SEK 1,499,999.63 and the number of shares has been determined on the basis of a subscription price that corresponds to the volume-weighted average price of CombiGene’s share during a period of fifteen (15) trading days ending the day before the board’s decision on the issue of shares. The new shares will be transferred to Lipigon as soon as the issue has been registered with the Swedish Companies Registration Office.